<DOC>
	<DOC>NCT00417573</DOC>
	<brief_summary>- This is the first study, that we are aware of, that will evaluate the efficacy of IgIV in patients with IgG subclass deficiency. - Will provide data for further collaboration in extending study to involve other immunological centers in the United States to study patients with similar disease.</brief_summary>
	<brief_title>Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections</brief_title>
	<detailed_description>*10 consenting adults (18 or older) will receive IgIV (Gamunex 10%) monthly at a dose of 400mg/kg body weight IV at 3ml/minute. Comprehensive labs will be monitored at each visit, as well as clinical eval, plus patients will complete a questionnaire each time. There is also a 3 month follow-up visit after completion of therapy. Specific xrays will be done at the beginning and with the last treatment.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>IgG Deficiency</mesh_term>
	<criteria>Adult (18 or older) with deficiency in one or more IgG subclasses with documented history of recurrent infections limited to upper or lower respiratory tract, urinary, and/or skin. Patients with panhypogammaglobulinemia or selective IgA deficiency.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Immunodeficiency</keyword>
	<keyword>Gammaglobulin</keyword>
	<keyword>IgG subclass deficiency with recurrent infections</keyword>
</DOC>